MOLECULAR THERAPY NUCLEIC ACIDS

|

Elsevier
Netherlands
MEDICINE
Significant Science Journal
English
Gold OA
T2
/

Publishing Information

/
Singe-blind

Founding year

/

Publishing Frequency

4

Number of articles per year

301

(2023)

Rejection Rate

56%

(2024)

Open Access

CC BY | CC BY-NC-ND

Content

Research Article; INS; Review
No
reproducible
Open Submission
Molecular Therapy Nucleic Acids is an international, open-access journal publishing top-quality basic, translational, and clinical research in the broad fields of nucleic-acid-based therapeutics to treat and/or correct genetic and acquired disease. As an official journal of the American Society of Gene & Cell Therapy, Molecular Therapy Nucleic Acids builds upon the success of Molecular Therapy in publishing important peer-reviewed research, cutting-edge reviews, and commentaries targeted to advances in gene- and oligonucleotide-based therapies. Subject areas include but are not limited to: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA-based therapeutics, applications of gene-modifying agents including triplex-forming oligonucleotides and enzymes such as Zn finger nucleases, pre-clinical target validation, safety/efficacy studies, and clinical trials. To accommodate the rapid growth of Molecular Therapy Nucleic Acids, starting in 2022, articles will be submitted and published in one of six subsections covering key topics. Subsections include:Bioinformatics